Your browser doesn't support javascript.
loading
Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: Scoping review and international consensus recommendations.
Nebgen, Denise R; Domchek, Susan M; Kotsopoulos, Joanne; de Hullu, Joanne A; Crosbie, Emma J; Paramanandam, Vincent Singh; Brood-van Zanten, Monique M A; Norquist, Barbara M; Guise, Theresa; Rozenberg, Serge; Kurian, Allison W; Pederson, Holly J; Yuksel, Nese; Michaelson-Cohen, Rachel; Bober, Sharon L; da Silva Filho, Agnaldo Lopes; Johansen, Nora; Guidozzi, F; Evans, D Gareth; Menon, Usha; Kingsberg, Sheryl A; Powell, C Bethan; Grandi, Giovanni; Marchetti, Claudia; Jacobson, Michelle; Brennan, Donal J; Hickey, Martha.
Afiliación
  • Nebgen DR; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Domchek SM; Basser Center for BRCA, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Kotsopoulos J; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada.
  • de Hullu JA; Department of Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Crosbie EJ; Division of Cancer Sciences, University of Manchester, St Mary's Hospital, Manchester, UK.
  • Paramanandam VS; Department of Obstetrics and Gynaecology, The Royal Women's Hospital, The University of Melbourne, Melbourne, Victoria, Australia.
  • Brood-van Zanten MMA; Department of Gynecology, The Netherlands Cancer Institute, Amsterdam University Medical Centres, Amsterdam, The Netherlands.
  • Norquist BM; Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA.
  • Guise T; Department of Endocrine Neoplasia and Hormone Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Rozenberg S; Department of Obstetrics and Gynaecology, Universite Libre de Bruxelles, Brussels, Belgium.
  • Kurian AW; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California, USA.
  • Pederson HJ; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA.
  • Yuksel N; Faculty of Pharmacy and Pharmaceutical Sciences, College of Health Sciences, University of Alberta, Edmonton, Alberta, Canada.
  • Michaelson-Cohen R; Department of Gynaecology and Medical Genetics Institute, Hebrew University Faculty of Medicine, Shaare Zedek Medical Centre, Jerusalem, Israel.
  • Bober SL; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.
  • da Silva Filho AL; Departamento de Ginecologia e Obstetricia da UFMG, Federal University of Minas Gerais, Belo Horizonte, Brazil.
  • Johansen N; Department of Gynaecology and Obstetrics, Sørlandet Hospital HF Arendal, Arendal, Norway.
  • Guidozzi F; Deparment of Obstetrics and Gynaecology, University of Witwatersrand, Johanesburg, South Africa.
  • Evans DG; University of Manchester, Prevent Breast Cancer Centre, Manchester, UK.
  • Menon U; MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.
  • Kingsberg SA; University Hospitals Cleveland Medical Center, Case Western University School of Medicine, Cleveland, Ohio, USA.
  • Powell CB; Kaiser Permanente Northern California, Hereditary Cancer Program, San Francisco, California, USA.
  • Grandi G; Department of Medical and Surgical Sciences for Mother, Child and Adult, University of Modena and Reggio Emilia, Modena, Italy.
  • Marchetti C; Department of Women's and Children's Health, Fondazione Policlinico Universitario A. Gemelli, IRCCS-Catholic University Sacred Heart, Rome, Italy.
  • Jacobson M; Women's College Hospital and Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Brennan DJ; UCD Gynaecological Oncology Group, UCD School of Medicine, Mater University Hospital, Dublin, Ireland.
  • Hickey M; Department of Obstetrics and Gynaecology, Research Precinct, Level 7, The Royal Women's Hospital, University of Melbourne, Parkville, Victoria, Australia.
BJOG ; 130(12): 1437-1450, 2023 11.
Article en En | MEDLINE | ID: mdl-37132126
ABSTRACT
Women at high inherited risk of ovarian cancer are offered risk-reducing salpingo-oophorectomy (RRSO) from age 35 to 45 years. Although potentially life-saving, RRSO may induce symptoms that negatively affect quality of life and impair long-term health. Clinical care following RRSO is often suboptimal. This scoping review describes how RRSO affects short- and long-term health and provides evidence-based international consensus recommendations for care from preoperative counselling to long-term disease prevention. This includes the efficacy and safety of hormonal and non-hormonal treatments for vasomotor symptoms, sleep disturbance and sexual dysfunction and effective approaches to prevent bone and cardiovascular disease.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Salpingooforectomía Tipo de estudio: Etiology_studies / Guideline / Risk_factors_studies / Systematic_reviews Límite: Adult / Female / Humans / Middle aged Idioma: En Revista: BJOG Asunto de la revista: GINECOLOGIA / OBSTETRICIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Salpingooforectomía Tipo de estudio: Etiology_studies / Guideline / Risk_factors_studies / Systematic_reviews Límite: Adult / Female / Humans / Middle aged Idioma: En Revista: BJOG Asunto de la revista: GINECOLOGIA / OBSTETRICIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos